Skip to main content
European Commission logo print header

Use flexible Tube Micro Plasma (FµTP) for Lipidomics

Project description

Novel biomarkers for early detection of cancer

Cancer is the second leading cause of mortality in EU countries after cardiovascular diseases. Early diagnosis can effectively reduce the mortality associated with cancer by providing treatment at the earliest possible stage. The EU-funded BIOplasma project will address the need for new non-invasive, fast and robust methods to detect different types of cancer in an early stage. Specifically, it is developing analytical tools that permit the diagnosis of biological tissues. Its novel analytical strategy, which is based on liquid chromatography/mass spectrometry, uses flexible tube micro plasma. The plasma serves as an ionisation source for the identification and quantification of several lipid biomarkers in body fluids.

Objective

Cancer is the leading cause of death in economically developed countries and the second leading cause of death in developing countries. In 2015, over 8.8 million people died of cancer worldwide and the numbers are expected to rise above 13 million in 2030 . As a consequence, development of non-invasive, fast and robust methods to detect different types of cancer in an early stage are timely. BIOplasma addresses the essential need for analytical tools that permit the diagnosis of biological tissues. A novel analytical strategy based on the Liquid Chromatography/Mass Spectrometry (LC-MS) using flexible Tube Micro Plasma (FµTP) as ionization source for the identification and quantification of several lipid biomarkers in body fluids is proposed

Keywords

æ

Coordinator

LEIBNIZ-INSTITUT FUR ANALYTISCHE WISSENSCHAFTEN-ISAS-EV
Net EU contribution
€ 162 806,40
Address
Bunsen kirchhoff strasse 11
44139 Dortmund
Germany

See on map

Region
Nordrhein-Westfalen Arnsberg Dortmund, Kreisfreie Stadt
Activity type
Research Organisations
Links
Other funding
€ 0,00